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OBJECTIVES We sought to examine the short- and long-term clinical consequences of ischemic
preconditioning (IP) during percutaneous coronary intervention (PCI).
BACKGROUND Ischemic preconditioning has been demonstrated in animal models to significantly diminish
the extent of myocardial necrosis consequent to coronary occlusion. Surrogate markers of
ischemic injury (ST segment shift, lactate release, creatine kinase release) in humans have
been shown to be similarly diminished with IP elicited during PCI. There are no studies of
the frequency of inducibility of IP during PCI, nor are there longer-term data on the clinical
relevance of IP.
METHODS A total of 382 patients underwent elective PCI employing a previously validated protocol to
elicit IP. Procedural, in-hospital, and one-year outcomes were recorded.
RESULTS Ischemic preconditioning was elicited in 80% of patients and was associated with a significant
reduction in the likelihood of in-hospital adverse cardiac events (IP group, 12.1%; non-IP
group, 44.1%; p  0.0001). Women and diabetic patients were less likely to exhibit IP. By
one year, patients failing to manifest IP were at significantly greater risk of post-discharge
death or non-fatal myocardial infarction (MI) (non-IP group, 25.9%; IP group, 11.1%; p 
0.002). Failure to manifest IP was significantly and independently associated with an
increased risk of death or non-fatal MI by one year.
CONCLUSIONS Clinically relevant short- and long-term cardioprotection can be found in association with IP
during PCI. In-hospital adverse ischemic events are significantly diminished in patients with
IP, as are the risks of death or non-fatal MI at one year. Failure to elicit IP during PCI serves
as an independent marker of increased risk of future ischemic events. (J Am Coll Cardiol
2003;42:998–1003) © 2003 by the American College of Cardiology Foundation
Since the original description in 1986 by Murry et al. (1),
ischemic preconditioning (IP) has been the subject of
intense investigation. Although this seminal study, per-
formed in a canine model, demonstrated the powerful effect
of IP on the extent of myocardial necrosis consequent to
coronary artery occlusion, similar observations have been
reported in other species (2–4) as well as with the use of
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surrogates for post-ischemic injury (5,6). Although an
analogous cardioprotective phenomenon has been suggested
in the clinical literature, these studies have, of necessity,
been limited to retrospective, inferential analyses (7–9) or
the use of surrogate end points after controlled coronary
occlusion during percutaneous coronary intervention (PCI)
(10–19). There are no data in the clinical literature address-
ing the frequency of the ability to elicit IP in an unselected
population of patients undergoing PCI nor are there data
relating the ability to elicit IP during PCI to subsequent
cardiovascular outcomes. Therefore, we performed a pro-
spective, longitudinal study in a series of patients undergo-
ing PCI using a previously validated protocol in order to
demonstrate the frequency of the ability to induce IP and to
compare clinical outcomes at one year in patients with and
without induced IP.
METHODS
The patient population for the present study was comprised
of all patients undergoing elective PCI from January 1997
through June 2001 by a single operator (W.L.) using a
validated IP protocol (vide infra). Patients were excluded
from consideration for the following: acute ST segment
elevation myocardial infarction (MI) (n  10); an abnormal
baseline electrocardiogram (ECG) (e.g., significant ST seg-
ment depression, left bundle-branch block precluding anal-
ysis of the ST segment shift during PCI) (n 13); ischemic
chest pain within 12 h of PCI (n  10); absence of
supporting evidence of myocardial ischemia (n  26);
ongoing administration of intravenous nitroglycerin (n 
5); refusal to grant permission to obtain clinical follow-up at
one year (n  6); inability to successfully complete the PCI
(n  4) (in these 4 patients persistent ST changes after the
first inflation precluded continuation of the protocol); he-
modynamic instability at any time during the PCI (n  3);
in-lab death (n  1); and participation in an extant
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investigational protocol (n  30). The final dataset was
comprised of 382 patients.
The protocol for the induction of IP during PCI has been
described and validated by our group (10,16,17) and others
(11–15,18,19). A 90-s period of balloon occlusion of the
target artery is followed by a 5-min period of unobstructed
reperfusion. A subsequent 90-s balloon occlusion at an
identical inflation pressure is then performed. The cali-
brated ST segment response is assessed from either the
surface ECG (n  306), using the leads that best corre-
spond to the distribution of the target artery and reporting
the maximal ST segment shift, or the electrogram record-
ing, using the intracoronary guide wire (n  76). In the
present investigation, the visual analog scale for pain assess-
ment (10,16) was not employed. Ischemic preconditioning
was considered present when the magnitude of ST segment
elevation at the completion of the second inflation was
reduced by at least 33% of the magnitude of the ST segment
elevation recorded during the first inflation. This cutoff repre-
sents the lower limit of the 95% confidence interval (CI) of the
mean magnitude of ST segment reduction reported in 10
recently published studies of IP during PCI (10–19).
Definitions and variables analyzed. In-lab significant ad-
verse clinical events (AEs) were defined as evolving Q-wave
MI, emergent coronary artery bypass surgery, side-branch
occlusion, significant (greater than National Heart, Lung,
and Blood Institute class B) dissection, distal embolization,
slow or no reflow, or abrupt vessel closure. In-hospital AEs
were defined as post-procedural death, urgent coronary
artery bypass surgery, and either Q-wave MI or a significant
increase (2  normal) in the post-procedural creatine
phosphokinase-MB fraction (CK-MB) obtained by 12 h
post procedure. Troponin levels were not routinely assessed
during this time period.
One-year clinical follow-up was obtained (99% of dis-
charged patients) by telephone interview conducted by an
individual not directly involved in the PCI (D.B.) and
included assessment of vital status and recurrent cardiovas-
cular events (death or MI). The diagnosis of MI was confirmed
in 80% of the events reported as such by review of the pertinent
hospital records. Consent for follow-up was obtained in accor-
dance with the requirements of the Institutional Review Board
of the University of Maryland, Baltimore.
Data analysis. Summary data are expressed as mean  SD
or median and interquartile intervals for continuous vari-
ables and percentages for categorical variables. Inter-group
comparisons were performed using an unpaired t test for
continuous, normally distributed variables and the Mann-
Whitney U test for non-parametric data. Pre- and post-PCI
ST segment shifts were compared using Wilcoxon signed
rank statistics. Contingency table analyses were used for the
comparison of categorical variables. The product limit
method was used to estimate time-dependent outcome
(death or non-fatal MI) rates. Log-rank statistics were used
in the comparison of these time-dependent outcomes be-
tween the IP and non-IP groups. Finally, after satisfying
proportionality assumptions, Cox proportional hazards
analysis controlling for those covariates demonstrating an
association with outcome on univariate analysis was used to
examine the relationship of IP to outcomes at one year.
Hazard ratios and their 95% CI are reported. Statistical
significance was achieved when p  0.05. All analyses were
performed using Statview, version 5.0 (SAS Institute, Inc.,
Cary, North Carolina).
RESULTS
The clinical and angiographic characteristics of the study
population are typical for patients undergoing elective con-
temporary PCI (Table 1). The mean age was 64 years.
Seventy-six percent were male. Forty-four percent were
undergoing PCI, having presented with an acute coronary
syndrome. Twenty-four percent exhibited significantly de-
creased left ventricular systolic function (ejection fraction
40%). Thirty-one percent were diabetic subjects requiring
oral hypoglycemics and/or supplemental insulin for control.
Thirty-three percent had clinically significant co-morbidity.
Overall, stent implantation was performed in 66% of pa-
tients (IP: 65%; non-IP: 68%; p  NS); the remainder
underwent conventional balloon angioplasty (IP: 35%; non-
IP: 32%; p  NS). All patients were discharged receiving a
daily dose of aspirin and, in the case of stent implantation,
ticlopidine or clopidogrel for at least one month. Overall
glycoprotein IIb/IIIa antagonist use was 25% (IP: 23%;
non-IP: 26%; p  NS).
Ischemic preconditioning, as previously defined, was
elicited in 80% of patients. Differences between patients
manifesting IP and those without IP are summarized in
Table 1. Patients who failed to manifest IP were more likely
to be older, female, and diabetic. As seen in Table 2 and
Figure 1, the decrease in ST segment elevation from
Inflation 1 to Inflation 2 was significantly greater in patients
with IP (mean change in IP group, 5.7  1.7 mV; mean
change in non-IP group, 0.1  0.6 mV; p  0.0001).
Notably, although many patients without IP exhibited ST
segment elevation during the initial balloon inflation, the
magnitude of this shift was significantly less than that seen
in the IP group (Table 2).
As can be seen in Figure 1B, there was a non-uniform
distribution of the ST segment responses during the first
inflation in the non-IP group. There were no identifiable
clinical or demographic features that distinguished patients
with 2 mV of ST segment deviation from those with
Abbreviations and Acronyms
AE  adverse clinical event
CI  confidence interval
CK-MB  creatine phosphokinase-MB fraction
ECG  electrocardiogram/electrocardiograph(ic)
IP  ischemic preconditioning
MI  myocardial infarction
PCI  percutaneous coronary intervention
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2 mV of ST segment deviation. Importantly, the propor-
tion of patients with surface ECG recordings was similar in
the IP (81%) and non-IP groups (76%; p  NS). When
patients in the non-IP group with 2 mV of ST segment
elevation during the first inflation (Fig. 1B) were excluded
from analysis, the magnitude of ST segment elevation in the
IP group (10.4  1.7 mV) remained significantly higher
than in the non-IP group (7.8  1.5 mV; p  0.001).
Overall in-lab procedural success (angiographic success
without in-lab AE) was achieved in 95% of patients, and
Table 1. Characteristics of Patient Population
Total
Study Population
(n  382)
IP Group
(n  305)
Non-IP
Group
(n  77)
p
(IP vs. Non-IP)
Mean age (yrs) 64  10 63  9 65  10 0.07
Female (%) 24 21 38 0.001
Clinical presentation (%) NS
Acute coronary syndrome 44 44 40
s/p thrombolysis 24 23 33
Chronic stable angina 32 33 27
Angiographic extent of disease (%) NS
Single-vessel disease 68 69 62
Double-vessel disease 23 22 28
Triple-vessel disease 9 9 10
Ejection fraction 0.4 (%) 24 23 28 NS
Co-morbidity (%) NS
Peripheral vascular disease 7.6 7.5 7.7
Chronic renal insufficiency 6.5 5.9 9.0
Cerebrovascular disease 6.8 6.5 7.7
Congestive heart failure 12.0 11.1 15.5
Diabetes mellitus (%) 31 25 54  0.0001
Target vessel (%) NS
LAD 44 45 39
LCx 19 18 20
RCA 33 33 32
Bypass graft 4 4 9
Lesion complexity (%) NS
C 40 38 47
Non-C 60 62 53
Beta-blocker use (%) NS
Pre-procedure 75 74 75
On discharge 83 83 83
Statin use (%) NS
Pre-procedure 68 68 71
On discharge 82 83 78
IP ischemic preconditioning; LAD left anterior descending coronary artery; LCx left circumflex coronary artery; RCA
right coronary artery; s/p  status post.
Table 2. Procedural Data and Outcomes
IP
(n  305)
Non-IP
(n  77)
p
(IP vs. non-IP)
ST segment shift (mV)
Inflation 1 10.4  1.7 5.1  4.1  0.0001
Inflation 2 4.7  1.7 5.0  4.0 NS
Procedural adverse event rate 4.9% 9.0% 0.15
Abrupt vessel closure (3) (2)
Side branch loss (2) (1)
Emergent CABG (1) (0)
Q-wave myocardial infarction (2) (1)
No reflow (3) (1)
Dissection (4) (2)
In-hospital adverse event rate 12.1% 44.1%  0.0001
Death (0) (0)
CABG (1) (1)
Abrupt vessel closure/stent thrombosis (1) (1)
Creatine kinase elevation (35) (32)
Numbers in parentheses represent number of patients.
CABG  coronary artery bypass graft surgery; IP  ischemic preconditioning.
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in-hospital procedural success (in-lab procedural success
without in-hospital AE) was achieved in 81%. The vast
majority (95%) of in-hospital AEs was the result of a
post-procedural increase in CK. The frequency of CK-MB
release in patients with IP (11.4%) was significantly lower
than in patients without IP (41.5%; p 0.0001). As seen in
Table 2, there was a non-significant trend toward lower
in-lab procedural success in patients without IP. However,
in-hospital procedural success was significantly lower in
patients failing to manifest IP, reflecting the increased AE
rate in this group (IP group 12.1%; non-IP group 44.1%;
p  0.0001).
At one year, the overall event rate of death/non-fatal MI
was 14.1% (95% CI: 10.6%, 17.6%). There were fewer
post-discharge adverse events (death/non-fatal MI) in the
IP group (cumulative event rate in IP group, 11.1%;
cumulative event rate in non-IP group, 25.9%; p  0.002).
As depicted in Figure 2, patients failing to manifest IP
during PCI were at significantly greater risk of death/MI
over the year after the procedure (log-rank p 0.001). This
increased risk was apparent as early as 50 days after PCI and
continued to increase over the follow-up period. These
results were unchanged when the group of non-IP patients
with2 mV ST segment deviation during the first inflation
were excluded from analysis (log-rank p  0.0004). Fur-
thermore, there was no significant difference in the rates of
death/non-fatal MI between non-IP patients with 2 mV
ST segment deviation during the first inflation and those
with 2 mV ST segment deviation (2  0.68, p  0.4).
When the analysis was restricted to mortality at one year,
a significantly increased risk was again seen in the patients
failing to manifest IP despite the small number of deaths in
each group (6 deaths in the IP group; 10 deaths in the
Figure 2. Kaplan-Meier plot of the estimated rates of freedom from death
or non-fatal MI during the year after hospital discharge. There was a highly
statistically significant reduction in event-free survival (log-rank p 0.001)
in patients failing to manifest ischemic preconditioning (IP) during PCI.
Figure 1. (A) (left panel) Histogram depicting the distribution of ST segment shift (mV) during the first inflation in patients manifesting ischemic
preconditioning (IP). The median (25th, 75th percentile) values were 10.0 (9.0, 12.0) mV. In all panels, the number of patients is indicated on the y-axis.
(Right panel) Histogram depicting the distribution of ST segment shift (mV) during the second inflation in patients manifesting IP. Notice the overall
shift to the left of the distribution indicating a significant reduction in the magnitude of ST segment elevation during Inflation 2. The median (25th, 75th
percentile) values were 5.0 (4.0, 6.0) mV. (B) (left panel) Histogram depicting a bimodal distribution of ST segment shift (mV) during the first inflation
in patients failing to manifest IP. Notice the overall leftward shift compared with A, indicating a reduced extent of ST segment elevation. The median (25th,
75th percentile) ST segment shift was 6.0 (2.0, 8.0) mV. (Right panel) Histogram depicting the distribution of ST segment shift (mV) during the second
inflation in patients failing to manifest IP. The distributions are virtually superimposable, indicating no overall change from the first to second inflations.
The median (25th, 75th percentile) ST segment shift was 6.0 (2.0, 8.0) mV.
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non-IP group; log-rank p 0.001). Using Cox proportional
hazards regression, the reduction in the mortality risk at one
year associated with IP was highly significant (hazard ratio
0.12; 95% CI 0.03, 0.38).
The importance of the ability to elicit IP during PCI was
confirmed on multivariate analysis after adjusting for the
covariates recorded in Table 1. Using Cox proportional
hazards analysis, the statistically significant independent
predictors of death or non-fatal MI at one year were
presentation with an acute coronary syndrome and mul-
tivessel coronary artery disease, whereas the use of beta-
blockers and the ability to elicit IP were associated with a
diminished risk of death or MI (Table 3).
DISCUSSION
In this report we describe, for the first time, the incidence
and clinical significance of the ability to induce IP during
elective PCI. Ischemic preconditioning could be elicited in
80% of patients using a standardized protocol. The frequency
of post-procedural cardiac enzyme elevation was significantly
lower in patients manifesting IP. Importantly, the risks of
death and death/non-fatal MI at one year were reduced by
85% and 55%, respectively, in patients manifesting IP. Multi-
variate analysis confirmed (the absence of) IP as an indepen-
dent predictor of death/MI at one year after PCI.
Since the original description of IP by Murry et al. (1), this
potent cardioprotective phenomenon has been validated in
numerous animal models, thereby underscoring its biologic
importance. Despite extensive investigations into the cellular
and molecular basis of IP, there is no consensus at present on
the precise mechanism(s) whereby myocytes develop tolerance
to more ischemia (20). Increasing attention has focused on the
mitochondrial adenosine triphosphate-dependent potassium
channel as a “final common pathway” (20–22), and numerous
agonists are believed to mediate their respective precondition-
ing effect via this mechanism (23). However, the molecular
bases for pharmacologically induced versus physiologically
induced IP may be distinct (24).
In contrast to the experimental literature, there is con-
siderable debate over the clinical relevance of IP in humans
(23,25). As no study in humans can rigorously duplicate the
experimental situation (brief ischemia followed by pro-
longed ischemia with the intention to result in myocardial
necrosis), the clinical literature has resorted to the use of
surrogate markers and end points. Thus, the PCI model of
coronary occlusion (brief myocardial ischemia) has been
extensively validated in the clinical literature, whereas the
use of ST segment deviation (in contrast to myocardial
necrosis) has served as a surrogate marker of ischemic injury.
Additional surrogates of ischemic injury approaching quan-
tification of myocyte necrosis (but short of histopathologic
confirmation) include analysis of myocardial-specific pro-
teins (26,27), transmyocardial lactate release (10,15), and
regional myocardial contractile function (18). However, all
such studies in humans have been limited to the short-term
sequelae of IP. Retrospective observational studies (7–9), in
which IP was inferred from patient interviews of survivors of
MI, have suggested a potential clinical significance of IP in
terms of “hard” cardiovascular outcomes.
Ischemic preconditioning could not be elicited in 20% of
the patients undergoing the described protocol. On further
analysis, only female gender and diabetic status were signif-
icantly associated with the failure to induce IP. The sug-
gestion of an increased failure rate in older patients may
reflect the fact that either the variation in ages in each group
was insufficient to detect such an effect or that substantially
older patients, that is,75 years, were under-represented in
this series. We have previously reported on the failure to
elicit IP when PCI is performed within 12 h of an anginal
episode (16), which is why these patients were excluded
from participation. An intriguing observation not previously
reported is that many of the non-IP patients exhibited ST
segment elevation during the first balloon inflation. The
magnitude of the response was, however, significantly lower
than that seen in IP patients during the first inflation. Thus,
patients failing to manifest IP may still maintain the
capacity to manifest myocardial ischemia.
The absence of IP conferred increased short- and long-
term risk after PCI. As we have previously shown (26), the
likelihood of post-procedural CK elevation was significantly
decreased in patients manifesting IP. However, the in-
creased risk of death/MI at one year associated with the
failure to induce IP was independent of the association
between IP and CK elevation (and in-hospital AE) and
suggests a different mechanism whereby IP may confer long-
term benefit. Although older patients, diabetic patients, and
women were less likely to manifest IP, none of these potential
confounders were independently associated with death/non-
fatal MI at one year. That IP remained significantly, and
inversely, associated with the risk of death/non-fatal MI at one
year affirms the clinical significance of this phenomenon.
The failure to elicit IP during PCI (inability of ischemic
myocardium to “protect” itself) may reflect profound and
deleterious alterations in myocardial metabolism during
low-flow ischemia. Although a considerable literature has
accumulated on the metabolic alterations in preconditioned
myocardium (28), no information is currently available on
the metabolic features of myocardium that fails to manifest
IP. The inability of ischemic myocardium to “down-
regulate” its metabolic machinery (23) may predispose such
Table 3. Predictors of Adverse Clinical Events at One Year:
Results From Multivariate Analysis
Variable
Hazard
Ratio 95% CI p
Stable angina 0.33 0.11, 0.92 0.03
Multi-vessel disease 3.38 1.25, 9.09 0.01
Use of beta-blocker 0.09 0.05, 0.17  0.001
Ischemic preconditioning 0.45 0.24, 0.84 0.01
Ejection fraction 0.4 0.76 0.42, 1.37 NS
Diabetes mellitus 1.28 0.71, 2.31 NS
CI  confidence interval.
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tissue to be particularly vulnerable to repetitive or prolonged
ischemia. The clinical consequences of such vulnerability
would be reflected in a higher risk of death or non-fatal MI.
The present study was a prospective, observational cohort
analysis designed to assess the inducibility of IP in clinical
practice. Although a randomized design may have allowed
for a more equal distribution of variables in the two groups,
the strong relationship between IP and event-free survival
on multivariate analysis provides additional support for our
conclusions. This study did not take into account the effects,
if any, of delayed preconditioning (20,29). That a significant
ischemic response to the first balloon inflation was noted in
80% of our patients argues strongly against an undetected
effect of delayed preconditioning. If the latter were to
obtain, the magnitude of ST shift during the initial balloon
inflation would have been considerably less (30).
In summary, IP can be elicited in 80% of patients
undergoing elective PCI. The absence of IP is strongly
associated with the risk of death/non-fatal MI within the
year after PCI. The ability to elicit IP confers a significantly
diminished risk of death or non-fatal MI at one year.
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